-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GB-2064 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GB-2064 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GB-2064 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) Drug Details:...
-
Product Insights
NewPost-Polycythemia Vera Myelofibrosis (PPV-MF) – Drugs In Development, 2024
Empower your strategies with our Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Drugs In Development, 2024 report and make more profitable business decisions. Post-polycythemia vera myelofibrosis (PPV-MF) is a myeloproliferative blood cancer in which the bone marrow makes too many red blood cells. It may also result in the overproduction of white blood cells and platelets. Symptoms include heart attack, stroke, deep venous thrombosis, headaches, lack of concentration, and fatigue. The disease may be controlled by chemotherapy, transfusions, transplant, and medications. The Post-Polycythemia...
-
Product Insights
NewPost-Essential Thrombocythemia Myelofibrosis (Post-ET MF) – Drugs In Development, 2024
Empower your strategies with our Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) – Drugs In Development, 2024 report and make more profitable business decisions. Post-essential thrombocythemia myelofibrosis (post-ET MF) is a rare, chronic blood disorder characterized by the progression of essential thrombocythemia (ET), a type of myeloproliferative neoplasm (MPN), to myelofibrosis (MF). It represents an advanced stage in the continuum of MPNs, involving abnormal production and functioning of blood cells in the bone marrow. Essential thrombocythemia is characterized by the overproduction of platelets...
-
Product Insights
NewMyelofibrosis – Drugs In Development, 2024
Empower your strategies with our Myelofibrosis – Drugs In Development, 2024 report and make more profitable business decisions. Myelofibrosis is a rare bone marrow disorder where abnormal cells cause fibrous tissue buildup, impairing blood cell production. It's a type of myeloproliferative neoplasm, leading to an enlarged spleen, anemia, fatigue, and increased infection risk. JAK2, MPL, or CALR mutations often underlie this condition. Diagnosis involves blood tests, bone marrow biopsy, and imaging. Treatment aims to manage symptoms and might involve medications, blood...
-
Product Insights
NewLiver Cirrhosis – Drugs In Development, 2024
Empower your strategies with our Liver Cirrhosis – Drugs In Development, 2024 report and make more profitable business decisions. Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver, which affects the normal flow of blood through the liver. Symptoms include loss of appetite, itchy skin, weight loss, tiredness and weakness, and nausea. Treatment includes liver transplant surgery. The...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GB-1211 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GB-1211 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: GB-1211 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GB-1211 in Decompensated Cirrhosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GB-1211 in Decompensated Cirrhosis Drug Details: GB-1211 is under development for the treatment of liver cirrhosis,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GB-2064 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GB-2064 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.GB-2064 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) Drug Details:GB-2064 (PAT-1251)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GB-2064 in Post-Polycythemia Vera Myelofibrosis (PPV-MF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GB-2064 in Post-Polycythemia Vera Myelofibrosis (PPV-MF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.GB-2064 in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Drug Details:GB-2064 (PAT-1251) Is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tagtociclib in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tagtociclib in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tagtociclib in Metastatic Breast Cancer Drug Details: Tagtociclib (PF-07104091) is under...